Global Growth to Connect Imaging to the Cure Driving Impactful Regulatory Approvals and Expansion Imaging Endpoints (IE), based in Scottsdale Arizona with eight offices in six countries, announced today the promotion of Jatinder Kaur to Chief Operating Officer (COO). Jatinder… Read More
This is an excerpt from our free eBook, “Using 18FDG-PET and Other PET Agents in Oncology Clinical Trials.” To access the full eBook, click here. THE USE OF PET IN ONCOLOGY CLINICAL TRIALS 18F FDG PET Imaging in Solid Tumors… Read More
This is an excerpt from our free eBook, "Response Assessment in Lymphoma: The Lugano Classification and Beyond." To access the full eBook, click here. STANDARDIZING THE EVALUATION OF LYMPHOMA: HISTORICAL OVERVIEW Although Cheson 2007 criteria made significant improvements over the… Read More
Scottsdale, Arizona, June 14, 2022 – Imaging Endpoints (IE), an imaging CRO (iCRO) that provides comprehensive central imaging services and technology solutions throughout the clinical trial process, announced that the United States Patent and Trademark Office (USPTO) has approved the… Read More
June 2, 2022 - Due to the recent COVID-19-related shutdown of a factory in Shanghai, there is a nationwide shortage of intravenous iodinated contrast media (e.g., iohexol) which is expected to last for several more weeks. As a consequence of… Read More
April 21, 2022 - Imaging Endpoints is regularly looking at different and new designs for clinical trials. Our science expertise, and knowledge of the science behind the imaging, gives us the ability on a multidisciplinary level to develop the best… Read More
April 7, 2022 - The fusion of new therapeutics, imaging, and biomarker development is directing us into an advanced realm of healthcare delivery. Imaging Endpoints understands that every data point counts and is critical for successful trial completion, from Phase… Read More
March 31, 2022 - Imaging Endpoints congratulates Novartis for its recent Food and Drug Administration (FDA) approval of Locametz® and Pluvicto™. The FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen… Read More
March 23, 2022 - Last week Imaging Endpoints had a great opportunity to join the entire stakeholder community at the Immuno-Oncology 360° Conference (“IO360”) as a founding sponsor for the 8th consecutive year. Our CMO, Ron Korn, MD, Ph.D. presented… Read More
March 17, 2022 - Imaging Endpoints is at the IO360 Conference in New York from March 16th – 18th alongside the entire stakeholder community including scientists and experts in clinical trial design, from around the world. We’re proud that on… Read More
Featured Webinar:
Radiologic Analysis of COVID-19 Infection
June 23, 2020
